AstraZeneca Not Immune To ‘Expected’ China Slowdown
This article was originally published in PharmAsia News
Executive Summary
Like a number of other pharma multinationals, AstraZeneca's sales growth in China slowed in the second quarter, but the UK-based firm says this was expected and that it still foresees a double digit increase in the country over the rest of the year.